Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2007

View Archived Issues

Six-month study shows prevention of depressive relapses with agomelatine

Recent Atir patent discloses novel agents for male sexual dysfunction

Novel antiinfectious agent reported in recent patent literature

Recent patents report novel therapeutic agents for neurological disorders

AST-120 effective in pouchitis pilot study

MBP-8298 safe in phase III MAESTRO-01 multiple sclerosis trial

Minocycline beneficial in patients with acute stroke

Aida identifies potential targets in phase II trial with Rh-Apo2L

Dynavax starts environmental exposure chamber study of Tolamba

DepoDur modified-release injection approved in Australia

Aripiprazole ineffective in treating methamphetamine dependence

Avant and Celldex sign merger and provide update on future activity

Raptor establishes subsidiary and acquires first clinical-stage product

Kyowa Hakko and Kirin Pharma to merge

Can-Fite's CF-102 promotes liver tissue regeneration following partial hepatectomy

FDA and EMEA grant orphan drug status to SQ-109 for tuberculosis

Summit initiates phase I clinical trial of SMT-D002 for seborrhea in PD

Mutations in PEX2 identified as the cause of Zellweger syndrome

Dendreon completes enrollment in phase III trial of Provenge for advanced prostate cancer

Lu-AA-24530 enters phase II for mood and anxiety disorders

Oncolytics Biotech receives U.K. approval to evaluate Reolysin

Morria Biopharmaceuticals advances MRX-4 to phase I for allergic rhinitis

PAION commences phase I trial of Solulin

APITD1, a candidate tumor suppressor gene in neuroblastoma

Inhibitex begins phase I study of FV-100 for shingles

FDA accepts Wyeth's sNDA for Tygacil in CAP

FDA grants fast track designation to Phamasset's R-7128 in chronic HCV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...